Brendan Banfield's murder trial reaches its climax Friday with closing arguments after he testified he shot a man he found stabbing his wife. Prosecutors allege an elaborate murder-for-hire plot, while the defense claims a tragic act of self-defense.
Ethereum enters February 2026 under pressure, testing key support near $2,690 after a historically weak January. Analysts are divided on whether seasonal trends or shifting on-chain dynamics will dictate the month's direction.
Oil prices pulled back from multi-month highs on Friday amid broad market risk aversion, yet President Trump's intensified focus on Iran continues to inject a significant risk premium into the market, setting Brent crude for its strongest monthly gain in years.
After a volatile period that saw shares swing from steep declines to recent gains, investors are scrutinizing whether Weyerhaeuser's current price presents a buying opportunity. A deep dive into valuation metrics reveals a complex picture, with discounted cash flow and P/E ratio analyses telling conflicting stories.
A revised price target for Rithm Capital (NYSE: RITM) has prompted a fresh look at the mortgage REIT's prospects, with analysts weighing its strategic shifts against a complex macroeconomic backdrop.
Blue Owl Capital faces a wave of securities class actions alleging disclosure failures around liquidity and redemptions, casting a shadow over its robust alternative asset management platform. As legal pressures mount, the market weighs solid analyst backing against growing governance concerns, setting the stage for a pivotal earnings report.
Schneider National's Q4 2025 earnings fell short of expectations, pressured by a sharp late-year drop in freight demand and severe weather. While acknowledging near-term challenges, executives pointed to early signs of market normalization and detailed strategic cost actions aimed at positioning the carrier for an eventual upcycle.
Southside Bancshares (SBSI) reported a significant rebound in fourth-quarter earnings, driven by strategic repositioning of its securities portfolio and lower funding costs. While loan growth remained modest, executives outlined a cautious outlook for near-term margin improvement and detailed plans for technology investments and selective M&A in competitive Texas markets.
Despite a mixed analyst outlook, Morgan Stanley projects robust growth for Full Truck Alliance's core commission business, even as overall revenue faces headwinds. The digital freight platform's long-term strategy is gaining favor.
RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.
Truist Securities has raised its price target for Amer Sports (NYSE: AS), citing the company's clear long-term roadmap and 'durable growth levers' across its portfolio of iconic sports brands. The firm sees a realistic path to earnings per share exceeding $2.50 by fiscal 2030.
As demand for specialist education soars, private investors—from Abu Dhabi to private equity firms—are capitalizing on a strained system, drawing criticism for extracting profits from vulnerable children and cash-strapped councils.
Buoyed by record bookings and strong financial performance in 2025, Royal Caribbean Group projects double-digit revenue growth for 2026. The cruise giant announced a major fleet expansion, including a new 'Discovery Class' and ten additional river cruise ships, signaling confidence in sustained consumer appetite for experiential travel.
PennyMac Mortgage Investment Trust (PMT) posted a strong Q4 profit of $52.36 million, defying a significant year-over-year revenue drop. This mixed performance has fueled a 12% stock rally over 90 days, raising questions about whether the current share price accurately reflects the company's future in a volatile mortgage market.
Apple is reportedly planning to prioritize the launch of its three highest-tier iPhone models in 2026, while delaying the rollout of a new standard edition, according to a Nikkei Asia report citing sources familiar with the matter. The move signals a strategic pivot towards the premium segment amid ongoing supply chain considerations.
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.
Keefe Bruyette trimmed its price target on Pagaya Technologies (PGY) to $35, while maintaining an Outperform rating. The adjustment comes despite the AI-driven lending platform reporting robust Q3 growth and a record partner pipeline.
Keefe Bruyette & Woods raises its price target on Riot Platforms (RIOT) to $23, citing a new long-term agreement with AMD that provides revenue visibility and supports the company's high-performance computing strategy.
The UK-based payments technology firm Bango (LON:BGO) is showing early signs of a financial transformation, breaking into profitability and increasing its capital deployment. While its return on capital remains below the software industry average, the underlying trend suggests a company in the midst of a strategic pivot.
